Abstract：Objective To observe the effect of Ginkgo Biloba Injection on the prognosis of patients with acute exacerbation chronic obstructive pulmonary disease (AECOPD) stage and to explore its mechanism.Methods From November 2016 to November 2017, 60 patients with AECOPD in the department of respiratory medicine of our hospital were selected and divided into observation group and control group by random number method, each had 30 cases, control group accepted conventional symptomatic treatment (oxygen, spasmolysis, anti-infection, etc.), on the basis of conventional treatment, the observation group was supplemented with Ginkgo Biloba Injection (20 mg plus 0.9% sodium chloride injection 250 ml, intravenous infusion, once per day, course of treatment for 14 days).Therapeutic effect, C-reactive protein,D-dimer,whole blood viscosity(BV),plasma viscosity(PV),blood gas analysis(oxygen partial pressure[PO2],carbon dioxide partial pressure [PCO2])were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P＜0.05).The C-reactive protein, D-dimer, BV, PV, and PCO2 of the observation group after treatment were lower than those of the control group,and PO2 was higher than that of the control group,and the differences were statistically significant(P＜0.05).Conclusion Ginkgo Biloba Injection has a good effect on prognosis in the adjuvant the therapy of AECOPD stage.
阎昱升；汤渝玲. 银杏叶注射液对慢性阻塞性肺疾病急性加重期患者预后的影响[J]. 中国当代医药, 2020, 27(22): 37-40.
YAN Yu-sheng；TANG Yu-ling. Effect of Ginkgo Biloba Injection on the prognosis of patients with chronic obstructive pulmonary disease at acute exacerbation stage. 中国当代医药, 2020, 27(22): 37-40.
Global Initiative for Chronic Obstructive Lung Disease.Global strategy for the diagnosis，management，and prevention of chronic obstructive pulmonary disease （2018）[EB/OL].https://www.researchgate.net/publication/313711652_Glo bal_strategy_for_the_diagnosis_management_and_prevention_of_chronic_obstructive_pulmonary_disease_Revised_2011.
[2]
Dhital R，Basnet S，Paudel P，et al.Prevalence of chronic obstructive pulmonary disease （COPD）among rheumatoid arthritis：results from national inpatient database[J].J Community Hosp Intern Med Perspect，2018，8（4）：211-214.
[3]
Wang C，Xu J，Yang L，et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China （the China Pulmonary Health [CPH] study）：a national cross-sectional study[J].Lancet，2018，391（10131）：1706-1717.
Vogelmeier CF，Criner GJ，Martinez FJ，et al.Global strategy for the diagnosis，management，and prevention of chronic obstructive pulmonary disease 2017 report.GOLD Executive Summary[J].Am J Respir Crit Care Med，2017，195（5）：557-582.
[11]
Turino GM.Chronic obstructive pulmonary disease.A biomarker and a potential therapy[J].Ann Am Thorac Soc，2018，15（Suppl 1）：S15-S17.
[12]
Dimoulis A，Pastaka C，Tsolaki V，et al.Non-invasive ventilation（NIV） and homeostatic model assessment（HOMA）index in stable chronic obstructive pulmonary disease（COPD）patients with chronic hypereapnic respiratory failure：a pilot study[J].Copd，2015，12（4）：427.
[13]
Pavord ID，Lettis S，Locantore N，et al.Blood eosinophils and inhaled corticosteroid/long-acting β2 agonist efficacy in COPD[J].Thorax，2016，71（2）：118-125.
京公网安备 11010502046607号